Advanced Lung Non-Small Cell Carcinoma Clinical Trial
Official title:
Tai-Chi and Aerobic Exercise to Improve Emotional Symptom Cluster in Late-stage Lung Cancer Patients
NCT number | NCT05778708 |
Other study ID # | UW22-583 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 13, 2023 |
Est. completion date | October 2026 |
The goal of this randomized controlled trial is to investigate the effects of Tai-Chi and aerobic exercise on the emotional symptom cluster, and the underlying mechanism of that cluster, in late-stage lung cancer patients. Participants will be randomized into one of three groups: 1) Tai-Chi group, 2) aerobic exercise group, or 3) self-management control group. Both the Tai-Chi and aerobic exercise groups will attend twice-weekly group classes for 16 weeks (32 total contact hours). The self-management control group will receive written information regarding the recommended level of physical activity.
Status | Recruiting |
Enrollment | 318 |
Est. completion date | October 2026 |
Est. primary completion date | February 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - diagnosed with stage IIIB or IV non-small cell lung cancer confirmed by pathology, with no other cancer diagnosis within the previous year; - a current Eastern Cooperative Oncology Group Performance Status of 0-2; - experience of sleep disturbance, anxiety, depression, and fatigue in the past week (rating of 1 or more on a 0-10 numeric rating scale [NRS] for each symptom); - able to communicate in Cantonese, Mandarin, or English; - conscious and alert Exclusion Criteria: - suffering from a condition that hinders exercise performance (e.g., active neurological disorder, recent heart attack); - currently participating in any other exercise or mind-body classes; or 3) performing regular exercises, defined as at least 150 minutes of moderate-intensity exercise weekly |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Queen Mary Hospital | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
The University of Hong Kong | Queen Mary Hospital, Hong Kong |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline Emotional symptom cluster at 8 weeks | NRSs for assessing each symptom of sleep disturbance, anxiety, depression, and fatigue over the past 7 days will be used to measure emotional symptom cluster severity. Higher score indicates more severe symptoms. | 8 weeks | |
Primary | Change from Baseline Emotional symptom cluster at 16 weeks | NRSs for assessing each symptom of sleep disturbance, anxiety, depression, and fatigue over the past 7 days will be used to measure emotional symptom cluster severity. Higher score indicates more severe symptoms. | 16 weeks | |
Primary | Change from Baseline Emotional symptom cluster at 28 weeks | NRSs for assessing each symptom of sleep disturbance, anxiety, depression, and fatigue over the past 7 days will be used to measure emotional symptom cluster severity. Higher score indicates more severe symptoms. | 28 weeks | |
Secondary | Change from Baseline Sleep disturbance at 8 weeks | Measured by the Pittsburg Sleep Quality Index. The total score ranges from 0-21, with higher scores denoting poorer sleep. | 8 weeks | |
Secondary | Change from Baseline Sleep disturbance at 16 weeks | Measured by the Pittsburg Sleep Quality Index. The total score ranges from 0-21, with higher scores denoting poorer sleep. | 16 weeks | |
Secondary | Change from Baseline Sleep disturbance at 28 weeks | Measured by the Pittsburg Sleep Quality Index. The total score ranges from 0-21, with higher scores denoting poorer sleep. | 28 weeks | |
Secondary | Change from Baseline Fatigue at 8 weeks | Measured by the Brief Fatigue Inventory. Higher score denotes worse fatigue level. | 8 weeks | |
Secondary | Change from Baseline Fatigue at 16 weeks | Measured by the Brief Fatigue Inventory. Higher score denotes worse fatigue level. | 16 weeks | |
Secondary | Change from Baseline Fatigue at 28 weeks | Measured by the Brief Fatigue Inventory. Higher score denotes worse fatigue level. | 28 weeks | |
Secondary | Change from Baseline Anxiety and depression at 8 weeks | Measured by the Hospital Anxiety and Depression Scale. Higher score denotes higher level of anxiety and depression. | 8 weeks | |
Secondary | Change from Baseline Anxiety and depression at 16 weeks | Measured by the Hospital Anxiety and Depression Scale. Higher score denotes higher level of anxiety and depression. | 16 weeks | |
Secondary | Change from Baseline Anxiety and depression at 28 weeks | Measured by the Hospital Anxiety and Depression Scale. Higher score denotes higher level of anxiety and depression. | 28 weeks | |
Secondary | Change from Baseline Emotion regulation at 8 weeks | Measured by the Emotion Regulation Questionnaire. Higher scores indicating greater usage of that strategy. | 8 weeks | |
Secondary | Change from Baseline Emotion regulation at 16 weeks | Measured by the Emotion Regulation Questionnaire. Higher scores indicating greater usage of that strategy. | 16 weeks | |
Secondary | Change from Baseline Emotion regulation at 28 weeks | Measured by the Emotion Regulation Questionnaire. Higher scores indicating greater usage of that strategy. | 28 weeks | |
Secondary | Change from Baseline Mindfulness at 8 weeks | Measured by the Five Facet Mindfulness Questionnaire-Short Form. Higher score denotes higher mindfulness experience. | 8 weeks | |
Secondary | Change from Baseline Mindfulness at 16 weeks | Measured by the Five Facet Mindfulness Questionnaire-Short Form. Higher score denotes higher mindfulness experience. | 16 weeks | |
Secondary | Change from Baseline Mindfulness at 28 weeks | Measured by the Five Facet Mindfulness Questionnaire-Short Form. Higher score denotes higher mindfulness experience. | 28 weeks | |
Secondary | Change from Baseline Cardiorespiratory fitness at 8 weeks | Measured by the six-minute walk test. The distance walked at the end of 6 minutes will be measured in meters. | 8 weeks | |
Secondary | Change from Baseline Cardiorespiratory fitness at 16 weeks | Measured by the six-minute walk test. The distance walked at the end of 6 minutes will be measured in meters. | 16 weeks | |
Secondary | Change from Baseline Cardiorespiratory fitness at 28 weeks | Measured by the six-minute walk test. The distance walked at the end of 6 minutes will be measured in meters. | 28 weeks | |
Secondary | Change from Baseline agility at 8 weeks | Measured by the timed up-and-go test; unit: second. | 8 weeks | |
Secondary | Change from Baseline agility at 16 weeks | Measured by the timed up-and-go test; unit: second. | 16 weeks | |
Secondary | Change from Baseline agility at 28 weeks | Measured by the timed up-and-go test; unit: second. | 28 weeks | |
Secondary | Change from Baseline strength at 8 weeks | Measured by the sit-to-stand test; unit: number of times. | 8 weeks | |
Secondary | Change from Baseline strength at 16 weeks | Measured by the sit-to-stand test; unit: number of times. | 16 weeks | |
Secondary | Change from Baseline strength at 28 weeks | Measured by the sit-to-stand test; unit: number of times. | 28 weeks | |
Secondary | Change from Baseline balance at 8 weeks | Measured by the single-leg standing test; ; unit: second. | 8 weeks | |
Secondary | Change from Baseline balance at 16 weeks | Measured by the single-leg standing test; ; unit: second. | 16 weeks | |
Secondary | Change from Baseline balance at 28 weeks | Measured by the single-leg standing test; ; unit: second. | 28 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04396535 -
Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT04186988 -
[18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy
|
Early Phase 1 | |
Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
Recruiting |
NCT06096844 -
Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
|
Phase 3 | |
Recruiting |
NCT05166616 -
Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02983578 -
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03831932 -
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05096663 -
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05498389 -
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05967533 -
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
|
Phase 1 | |
Active, not recruiting |
NCT05334329 -
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
|
Phase 1 | |
Recruiting |
NCT04856176 -
A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
|
Phase 2 | |
Recruiting |
NCT05198154 -
ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC
|
||
Recruiting |
NCT04762199 -
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
|
Phase 1 | |
Active, not recruiting |
NCT04491942 -
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05407038 -
Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue
|
N/A | |
Recruiting |
NCT03191149 -
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
|
Phase 2 | |
Recruiting |
NCT06249282 -
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05339022 -
Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial
|
N/A | |
Recruiting |
NCT04902040 -
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
|
Phase 1/Phase 2 |